SCHEMBL3735442

SCHEMBL3735442

Cc1cc(Cl)c(OCCOc2ccccn2)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
HPGD P15428 5/20 0.52
L3MBTL1 Q9Y468 5/20 0.52
MAPK1 P28482 1/20 0.52
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 2/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
TDP1 Q9NUW8 1/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
REN P00797 3/20 0.39
MEN1 O00255 1/20 0.38
NPY1R P25929 1/20 0.38
NPY2R P49146 1/20 0.38
KMT2A Q03164 1/20 0.38
PDE4A P27815 1/20 0.37
GPR84 Q9NQS5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15986584 0.82 NPC1 (0.44) MAPTHPGDL3MBTL1MAPK1ALDH1A1
SCHEMBL4190714 0.77 KDM4E (0.50) HPGDL3MBTL1MAPK1ALDH1A1NPC1
SCHEMBL1750892 0.77 MAPT (0.48) MAPTHPGDL3MBTL1MAPK1ALDH1A1
SCHEMBL5795265 0.77 MAPT (0.58) MAPTHPGDL3MBTL1MAPK1ALDH1A1
SCHEMBL4980035 0.75 MAPT (0.46) MAPTHPGDL3MBTL1MAPK1ALDH1A1
SCHEMBL78925 0.74 L3MBTL1 (0.45) MAPTHPGDL3MBTL1MAPK1ALDH1A1
SCHEMBL3660700 0.74 KDM4E (0.50) MAPTHPGDL3MBTL1MAPK1ALDH1A1
SCHEMBL13538059 0.73 MAPT (0.44) MAPTHPGDL3MBTL1MAPK1ALDH1A1
SCHEMBL29784889 0.72 TSHR (0.44) HPGDL3MBTL1ALDH1A1NPC1CYP2D6
SCHEMBL165449 0.72 TSHR (0.44) HPGDL3MBTL1ALDH1A1NPC1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100280024-A1 RENIN INHIBITORS CADILA HEALTHCARE LIMITED (IN) 2010-11-04 US disclosed
WO-2010011584-A2 PROCESS FOR MAKING A RENIN INHIBITOR MERCK & CO., INC. (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280024-A1 RENIN INHIBITORS REN, ACE, AGTR1 MAPT 45/4885HPGD 599/4885L3MBTL1 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.